MucosaTec News and Insight

Tagesspiegel features us – again

tagesspiegel.de highlights, in an article, our success in winning a competition by the SPRIND agency of the Federal Ministry of Education and Research of Germany, and introduces the unique mechanism of action of our nasal spray currently in development. This nasal spray presents a novel approach in the creation of antiviral agents. With a significant … Read more

Tagesspiegel features us

The COVID-19 pandemic has highlighted the urgent need for antiviral agents, generating significant interest in related research. Tagesspiegel.de hits this spot by discussing the MucBoost research project, involving multiple partners and focusing on our new antiviral mechanism of action in a thorough article. With its extensive reach of 9.2 million unique users per month, tagesspiegel.de … Read more

YouTube video about the science behind our product

Learn more about the science behind our nasal spray in this video. The YouTube channel “Breaking Lab” presents the team MucBoost and other teams of the challenge “broad-spectrum antivirals”, which was launched by SPRIND, the Federal Agency for Disruptive Innovation – Germany. The MucBoost project is one of the winners of the challenge’s second stage

Pharmacists get informed

The newspage of the German Pharmacist Association (Pharmazeutische-Zeitung.de) features the the first level of the challenge „broad-spectrum antivirals“ by SPRIND – the Federal Agency for Disruptive Innovation – Germany with an article. Among the nine teams is the MucBoost project, from which MucosaTec GmbH is a spin-off. Pharmazeutische-Zeitung.de counted 3,470,205 page impressions and 1,733,170 visits … Read more